BPC-157's legal status in 2026, explained
In April 2026 the FDA took BPC-157 off its list of peptides with safety concerns for compounding. That is not an approval. Here is what changed and what didn't.
In April 2026 the FDA republished its interim list of bulk substances for compounding pharmacies and removed 12 peptides, BPC-157 among them, from Category 2, the group of substances flagged for safety concerns.
What that does not mean
- BPC-157 is not FDA-approved for any use.
- Leaving Category 2 does not, on its own, make a substance eligible for compounding. The FDA has said its status is still under evaluation.
- Products labelled "research use only" are still not drugs and are not checked by the FDA.
- BPC-157 remains on the World Anti-Doping Agency's prohibited list.
What to watch
An FDA advisory committee was scheduled to consider BPC-157 and other peptides in July 2026. We will update the BPC-157 page when the outcome is confirmed. Each peptide page shows the date its legal status was last checked.
Keep reading
Related peptides
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.